An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)
NCT ID: NCT01338545
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2010-07-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe rheumatoid arthritis (RA) of at least 6 months duration
* Non-responder or intolerant to at least one DMARD or TNF inhibitor treatment
* Initiated on treatment with RoActemra according to Summary of Product Characteristics (SPC) indications
Exclusion Criteria
* Pregnant or lactating women
* Patients who have started RoActemra treatment in a clinical trial or for compassionate use
* Treatment with any investigational drug in the previous 4 weeks (or at least 5 times the half-life of the drug)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Coral Springs, Florida, United States
Elche, Alicante, Spain
Elda, Alicante, Spain
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
Sabadell, Barcelona, Spain
Sant Joan Despí, Barcelona, Spain
Jerez de la Frontera, Cadiz, Spain
Santander, Cantabria, Spain
Torrelavega, Cantabria, Spain
Castellon, Castellon, Spain
Vinaròs, Castellon, Spain
Córdoba, Cordoba, Spain
Girona, Girona, Spain
Granada, Granada, Spain
Granada, Granada, Spain
Donostia / San Sebastian, Guipuzcoa, Spain
Huelva, Huelva, Spain
A Coruña, La Coruña, Spain
Santiago de Compostela, La Coruña, Spain
Logroño, La Rioja, Spain
Alcalá de Henares, Madrid, Spain
Alcorcón, Madrid, Spain
El Escorial, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Málaga, Malaga, Spain
Cartagena, Murcia, Spain
El Palmar, Murcia, Spain
Lorca, Murcia, Spain
Murcia, Murcia, Spain
Pamplona, Navarre, Spain
Ourense, Orense, Spain
Vigo, Pontevedra, Spain
Seville, Sevilla, Spain
Toledo, Toledo, Spain
Alzira, Valencia, Spain
San Juan, Valencia, Spain
Valencia, Valencia, Spain
Valencia, Valencia, Spain
Valencia, Valencia, Spain
Valenica, Valencia, Spain
Barakaldo, Vizcaya, Spain
Bilbao, Vizcaya, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25264
Identifier Type: -
Identifier Source: org_study_id